Patents by Inventor Fuqiang Zhu

Fuqiang Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11971038
    Abstract: A single-stage enthalpy enhancing rotary compressor and an air conditioner having same. The single-stage enthalpy enhancing rotary compressor includes: at least one single-stage cylinder, a rotator, an upper flange, and a lower flange. The rotator is arranged inside the cylinder and is rotatable, a compression chamber is formed between the rotator and an inner peripheral wall of the cylinder, a vapor injection opening is defined in at least one of the upper flange the lower flange, and the vapor injection opening is configured to supply gas outside the compressor to the compression chamber directly. According to the present disclosure, two-stage compression is realized without adding an extra cylinder, thereby effectively enhancing a circulation of refrigerant, improving cooling performance of the air conditioner under high environmental temperatures.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: April 30, 2024
    Assignee: GREE ELECTRIC APPLIANCES, INC. OF ZHUHAI
    Inventors: Guanghui Xia, Xiaocheng Lai, Shuo Xiong, Junchu Liang, Boming Zhu, Lihui Zhang, Wei Zhu, Xuechao Ding, Fuqiang Zhang, Hao Mei
  • Patent number: 11731965
    Abstract: The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: August 22, 2023
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, TOPHARMAN SHANGHAI CO., LTD.
    Inventors: Yang He, Xiangrui Jiang, Jianfeng Li, Yu Wang, Zhen Wang, Weiming Chen, Fuqiang Zhu, Chunhui Wu, Rongxia Zhang, Jingshan Shen, Hualiang Jiang
  • Publication number: 20220289684
    Abstract: The present disclosure relates to a benzimidazole-substituted phenyl-n-butyramide-based compound and the preparation method thereof. The method of the present disclosure avoids nitration reaction and polyphosphoric acid cyclization reaction, and avoids the generation of a large amount of waste acid reaction solution from the source. The synthesis method embodied in the invention has the advantages of simplicity and high efficiency, mild conditions and few pollutants, etc., and is suitable to be developed as a green and sustainable production process.
    Type: Application
    Filed: August 27, 2020
    Publication date: September 15, 2022
    Inventors: Jingshan SHEN, Changliang SUN, Fuqiang ZHU, Junchi ZHANG, Rui LI
  • Publication number: 20220227773
    Abstract: The present invention relates to a fused ring compound represented by general formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition and use thereof. The compound provided in the present invention is useful for treating, preventing and/or controlling various nervous system disorders. The compound provided in the present invention modulates one or more monoamine transporters, inhibits the reuptake of endogenous monoamines such as dopamine, 5-hydroxytryptamine, and norepinephrine (e.g., from the synaptic cleft), and/or modulates the 5-HT3 receptor.
    Type: Application
    Filed: May 29, 2020
    Publication date: July 21, 2022
    Inventors: Jingshan SHEN, Yang HE, Chunhui WU, Feipu YANG, Zhen WANG, Junchi ZHANG, Fuqiang ZHU, Hongjian QIN
  • Publication number: 20220204431
    Abstract: Disclosed is a method for preparing cannabidiol and analogues thereof; the method is implemented by means of reacting a resorcinol derivative with menthyl-2,8-dien-1-ol or a derivative thereof. The method of the present invention has advantages of such as high chemical reaction selectivity and simple operation.
    Type: Application
    Filed: May 15, 2020
    Publication date: June 30, 2022
    Inventors: Jingshan SHEN, Xudong GONG, Fuqiang ZHU, Xiangrui JIANG, Yan ZHANG, Changliang SUN
  • Publication number: 20200255421
    Abstract: The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.
    Type: Application
    Filed: August 14, 2018
    Publication date: August 13, 2020
    Inventors: Yang HE, Xiangrui JIANG, Jianfeng LI, Yu WANG, Zhen WANG, Weiming CHEN, Fuqiang ZHU, Chunhui WU, Rongxia ZHANG, Jingshan SHEN, Hualiang JIANG
  • Patent number: 9376410
    Abstract: This invention disclose (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone in a single configuration and preparation method and use thereof. The (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone, or a pharmaceutically acceptable salt, an ester, a prodrug or a solvate thereof according to the invention are important intermediates of a variety of anti-viral and anti-tumor active ingredients. A compound obtained from (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone via an acylation reaction can be directly used for preparing various anti-viral and anti-tumor drugs. The Chiral synthesis method and the spontaneous resolution method of the compound of (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone according to the invention have the following advantages: the reaction routes are short and simple with high yield and low cost, which are suitable for industrial application.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: June 28, 2016
    Assignees: TOPHARMAN SHANGHAI CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, TOPHARMAN SHANDONG CO., LTD.
    Inventors: Guan Wang, Xiangrui Jiang, Xudong Gong, Weiming Chen, Fuqiang Zhu, Rongxia Zhang, Xianguo Zhao
  • Publication number: 20160102047
    Abstract: The present invention relates to a (2R,3R)-3-(3-substituted phenyl)-2-methyl n-pentanamide compounds as shown in the formula I and the preparation method thereof, wherein, the substituents are as defined in the specification, the present invention further relates to a use of the above compounds for the preparation of tapentadol II or its pharmaceutically acceptable salt, and the intermediates involved in the preparation process
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Inventors: Qiang ZHANG, Rongxia ZHANG, Guanghui TIAN, Jianfeng LI, Fuqiang ZHU, Xiangrui JIANG
  • Patent number: 9249084
    Abstract: The present invention relates to a (2R,3R)-3-(3-substituted phenyl)-2-methyl n-pentanamide compounds as shown in the formula I and the preparation method thereof, wherein, the substituents are as defined in the specification, the present invention further relates to a use of the above compounds for the preparation of tapentadol II or its pharmaceutically acceptable salt, and the intermediates involved in the preparation process.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: February 2, 2016
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Topharman Shanghai Co., Ltd.
    Inventors: Qiang Zhang, Rongxia Zhang, Guanghui Tian, Jianfeng Li, Fuqiang Zhu, Xiangrui Jiang, Jingshan Shen
  • Publication number: 20150284351
    Abstract: This invention disclose (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone in a single configuration and preparation method and use thereof. The (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone, or a pharmaceutically acceptable salt, an ester, a prodrug or a solvate thereof according to the invention are important intermediates of a variety of anti-viral and anti-tumor active ingredients. A compound obtained from (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone via an acylation reaction can be directly used for preparing various anti-viral and anti-tumor drugs. The Chiral synthesis method and the spontaneous resolution method of the compound of (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone according to the invention have the following advantages: the reaction routes are short and simple with high yield and low cost, which are suitable for industrial application.
    Type: Application
    Filed: October 10, 2013
    Publication date: October 8, 2015
    Inventors: Guan Wang, Xiangrui Jiang, Xudong Gong, Weiming Chen, Fuqiang Zhu, Rongxia Zhang, Xianguo Zhao
  • Publication number: 20140046074
    Abstract: The present invention relates to a (2R, 3R)-3-(3-substituted phenyl)-2-methyl n-pentanamide compounds as shown in the formula I and the preparation method thereof, wherein, the substituents are as defined in the specification, the present invention further relates to a use of the above compounds for the preparation of tapentadol II or its pharmaceutically acceptable salt, and the intermediates involved in the preparation process.
    Type: Application
    Filed: January 31, 2012
    Publication date: February 13, 2014
    Inventors: Qiang Zhang, Rongxia Zhang, Guanghui Tian, Jianfeng Li, Fuqiang Zhu, Xiangrui Jiang, Jingshan Shen
  • Patent number: 8242264
    Abstract: The present invention relates to a process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof. The present invention provides a compound represented by formula I and a compound represented by formula II, and processes for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine by using the compound represented by formula I, the compound represented by formula II and o-nitrobenzaldehyde. The invention has the advantages of the shorter synthesis steps, easily available raw materials and simple operation. Moreover, the process is economic and safe by avoiding the use of expensive and dangerous lithium aluminum hydride.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: August 14, 2012
    Assignees: Topharman Shanghai Co., Ltd., Weifang Tehua Chemical Co., Ltd.
    Inventors: Fuqiang Zhu, Haihong Li, Wenzhong Wang, Hui Zhang, Jingshan Shen
  • Publication number: 20110144347
    Abstract: Provided is a process for the epimerization of the cis isomer of atovaquone, atovaquone intermediates and isomeric mixtures thereof into their corresponding trans-isomers resulting in higher yield of pure atovaquone.
    Type: Application
    Filed: June 30, 2008
    Publication date: June 16, 2011
    Applicant: CHEMAGIS LTD.
    Inventors: Fuqiang Zhu, Michel Bekhazi
  • Publication number: 20110137041
    Abstract: The invention provides novel intermediates of atovaquone and use thereof for the preparation of atovaquone
    Type: Application
    Filed: June 30, 2008
    Publication date: June 9, 2011
    Applicant: CHEMAGIS LTD.
    Inventors: Fuqiang Zhu, He Qiao, Michel Bekhazi
  • Publication number: 20100256358
    Abstract: The present invention relates to a process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof. The present invention provides a compound represented by formula I and a compound represented by formula II, and processes for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine by using the compound represented by formula I, the compound represented by formula II and o-nitrobenzaldehyde. The invention has the advantages of the shorter synthesis steps, easily available raw materials and simple operation. Moreover, the process is economic and safe by avoiding the use of expensive and dangerous lithium aluminum hydride.
    Type: Application
    Filed: May 22, 2008
    Publication date: October 7, 2010
    Applicants: TOPHARMAN SHANGHAI CO., LTD., WEIFANG TEHUA CHEMICAL CO., LTD.
    Inventors: Fuqiang Zhu, Haihong Li, Wenzhong Wang, Hui Zhang, Jingshan Shen